Taurolidine Lock SolutionTAURO-USE2NCT07259421
Survey of Practices Regarding the Use of Taurolidine Lock Solutions in Patients With Insertion of a Peripherally Inserted Central Catheter (PICC) in a Vascular Access Unit
An observational study of Taurolidine Lock Solution, run by University Hospital, Grenoble.
Trial summary
The primary objective of this study is to describe current practices regarding the administration of taurolidine lock solutions in relation to medical prescriptions for patients who have undergone peripherally inserted central catheter (PICC) implantation in the Vascular Access Unit as part of parenteral nutrition… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Taurolidine Lock Solution
- How many people
- 45 participants
- Where
- No sites listed yet
- Study dates
- Dec 2025to Mar 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: All patients meeting the inclusion criteria will be recruited consecutively over a three-month period to minimize the risk of selection bias.
Who may be able to join
- Patient who has undergone PICC placement in the vascular access unit with an indication for parenteral nutrition supplementation.
- Patient not opposed to participating in this research.
Who cannot join
- Patient not speaking French
- Patient under guardianship or conservatorship
- Patient with major neurocognitive disorders
- Patient with severe hearing impairment
- Patient who do not have a telephone
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
The primary objective of this study is to describe current practices regarding the administration of taurolidine lock solutions in relation to medical prescriptions for patients who have undergone peripherally inserted central catheter (PICC) implantation in the Vascular Access Unit as part of parenteral nutrition therapy. Our underlying hypothesis is that the use of taurolidine lock solutions may deviate from current recommendations, particularly with respect to administration procedures.
This study will allow us to characterize the use of taurolidine lock solutions in relation to medical prescriptions, identify potential deviations from recommended practices, and document any associated adverse events. It will also enable follow-up of PICC outcomes at 8 and 30 days after implantation in the Vascular Access Unit, whereas current follow-up is performed only at 8 days post-insertion.
- Conditions
- Taurolidine Lock Solution
- Keywords
- vascular access unit, parenteral nutrition, peripherally inserted central catheter, catheter related infection, health care-associated infection, taurolidine, lock solution, survey of practices
- Medical subject headings
- Hyperphagia, Catheter-Related Infections, Cross Infection
What is being measured
The primary outcome is the main question the study is designed to answer.
To characterize, through an assessment of current practices, the administration of taurolidine lock solutions as prescribed for patients who have undergone PICC implantation in the Vascular Access Unit as part of parenteral nutrition therapy.
Proportion of patients with a prescription for a taurolidine lock solution who actually receive administrations of the prescribed lock solution (concordance between prescribed and administered product).
Proportion of patients for whom lock solutions are administered in accordance with the manufacturer's instructions for use; compliant administration is defined as the nurse performing all recommended steps for applying the lock solution at the end of each parenteral nutrition infusion.
Proportion of patients for whom lock solutions are withdrawn in accordance with the manufacturer's instructions for use (lock solutions aspirated before catheter use).
Proportion of patients for whom lock solutions are disposed of in accordance with regulations for biological-hazard waste.
Measured: Eight and thirty days after PICC placement in the Vascular Access Unit
Secondary outcomes (11)
Describe nurses' perceptions of their own knowledge regarding the use of taurolidine lock solutions.
Quantify, using a self-assigned score, nurses' level of knowledge concerning taurolidine lock solutions.
Proportion of nurses aware of the various properties of lock solutions according to the references available on the market.
Measured: Eight and thirty days after PICC placement in the Vascular Access Unit.
Describe the medical care provided by home service providers for patients receiving a PICC placement for parenteral nutrition supplementation.
Nature and number of service providers working with patients at home.
Measured: Eight and thirty days after PICC placement in the Vascular Access Unit.
Describe the supply chain for taurolidine lock solutions.
Nature and proportions of procurement methods for taurolidine lock solutions for patients at home.
Measured: Eight and thirty days after PICC placement in the Vascular Access Unit.
Describe the elements related to PICC placement.
Nature and proportions of elements related to PICC placement: number of lumens, vein of insertion, side of insertion, duration of placement, and role of the inserter (nurse anesthetists or physician).
Measured: Eight and thirty days after PICC placement in the Vascular Access Unit.
Characterize the functional status of the PICC over time.
Proportion of PICC in place and functional at 8 and 30 days post-insertion, defined as not requiring premature removal and allowing infusion and blood sampling.
Measured: Eight and thirty days after PICC placement in the Vascular Access Unit.
Describe complications related to PICC placement.
Nature and proportions of complications related to the PICC occurring within 8 and 30 days post-insertion.
Measured: Eight and thirty days after PICC placement in the Vascular Access Unit.
Describe the causes of premature PICC removal.
Nature and proportions of causes for premature PICC-line removal within 8 and 30 days post-insertion.
Measured: Eight and thirty days after PICC placement in the Vascular Access Unit.
Describe adverse events related to the use of taurolidine lock solutions.
Nature and proportion of adverse events potentially related to the use of a taurolidine lock solution, as reported by patients or healthcare providers.
Measured: Eight and thirty days after PICC placement in the Vascular Access Unit.
Describe the difficulties encountered by healthcare professionals when using taurolidine lock solutions.
Nature and proportion of difficulties encountered by home-care nurses when using taurolidine lock solutions.
Measured: Eight and thirty days after PICC placement in the Vascular Access Unit.
Describe the information sources used by healthcare professionals regarding taurolidine lock solutions.
Nature and proportion of information sources consulted by nurses in the event of problems related to the use of a taurolidine lock solution or to the use of the PICC.
Measured: Eight and thirty days after PICC placement in the Vascular Access Unit.
Characterize the use of device vigilance in the event of adverse events related to taurolidine lock solutions.
Proportion of nurses who would report to device vigilance any adverse events related to the use of a taurolidine lock solution or to the use of the PICC, should such events occur.
Measured: Eight and thirty days after PICC placement in the Vascular Access Unit.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Dec 2025
- Study startDec 2025 (estimated)
- Primary completionMar 2026 (estimated)
- Study completionMar 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Taurolidine Lock SolutionStudies of the same condition, open and under way.
- More trials run by University Hospital, GrenobleThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 45 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Grenoble
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07259421
- Sponsor's protocol ID
- 38RC25.0315.
- Acronym
- TAURO-USE2
- Status last verified
- Nov 2025
- First submitted
- 17 Nov 2025
- Last updated
- 2 Dec 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 2 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Survey of Practices Regarding the Use of Taurolidine Lock Solutions in Patients With Insertion of a Peripherally Inserted Central Catheter (PICC) in a Vascular Access Unit
- ClinicalTrials.gov ID
- NCT07259421
- Acronym / sponsor ID
- TAURO-USE2 / 38RC25.0315.
- Conditions
- Taurolidine Lock Solution
- Keywords
- vascular access unit, parenteral nutrition, peripherally inserted central catheter, catheter related infection, health care-associated infection, taurolidine, lock solution, survey of practices
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 45 participants (estimated)
- Lead sponsor
- University Hospital, GrenobleUniversity, hospital or other
- Study start
- Dec 2025 (estimated)
- Primary completion
- Mar 2026 (estimated)
- Study completion
- Mar 2026 (estimated)
- First posted
- 2 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary objective of this study is to describe current practices regarding the administration of taurolidine lock solutions in relation to medical prescriptions for patients who have undergone peripherally inserted central catheter (PICC) implantation in the Vascular Access Unit as part of parenteral nutrition therapy. Our underlying hypothesis is that the use of taurolidine lock solutions may deviate from current recommendations, particularly with respect to administration procedures.
This study will allow us to characterize the use of taurolidine lock solutions in relation to medical prescriptions, identify potential deviations from recommended practices, and document any associated adverse events. It will also enable follow-up of PICC outcomes at 8 and 30 days after implantation in the Vascular Access Unit, whereas current follow-up is performed only at 8 days post-insertion.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- All patients meeting the inclusion criteria will be recruited consecutively over a three-month period to minimize the risk of selection bias.
Key inclusion criteria (2 listed)
- Patient who has undergone PICC placement in the vascular access unit with an indication for parenteral nutrition supplementation.
- Patient not opposed to participating in this research.
Key exclusion criteria (5 listed)
- Patient not speaking French
- Patient under guardianship or conservatorship
- Patient with major neurocognitive disorders
- Patient with severe hearing impairment
- Patient who do not have a telephone
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
To characterize, through an assessment of current practices, the administration of taurolidine lock solutions as prescribed for patients who have undergone PICC implantation in the Vascular Access Unit as part of parenteral nutrition therapy.
Time frame: Eight and thirty days after PICC placement in the Vascular Access Unit
Proportion of patients with a prescription for a taurolidine lock solution who actually receive administrations of the prescribed lock solution (concordance between prescribed and administered product). Proportion of patients for whom lock solutions are administered in accordance with the manufacturer's instructions for use; compliant administration is defined as the nurse performing all recommended steps for applying the lock solution at the end of each parenteral nutrition infusion. Proportion of patients for whom lock solutions are withdrawn in accordance with the manufacturer's instructions for use (lock solutions aspirated before catheter use). Proportion of patients for whom lock solutions are disposed of in accordance with regulations for biological-hazard waste.
11 secondary outcomes
Describe nurses' perceptions of their own knowledge regarding the use of taurolidine lock solutions.
Time frame: Eight and thirty days after PICC placement in the Vascular Access Unit.
Describe the medical care provided by home service providers for patients receiving a PICC placement for parenteral nutrition supplementation.
Time frame: Eight and thirty days after PICC placement in the Vascular Access Unit.
Describe the supply chain for taurolidine lock solutions.
Time frame: Eight and thirty days after PICC placement in the Vascular Access Unit.
Describe the elements related to PICC placement.
Time frame: Eight and thirty days after PICC placement in the Vascular Access Unit.
Characterize the functional status of the PICC over time.
Time frame: Eight and thirty days after PICC placement in the Vascular Access Unit.
Describe complications related to PICC placement.
Time frame: Eight and thirty days after PICC placement in the Vascular Access Unit.
Describe the causes of premature PICC removal.
Time frame: Eight and thirty days after PICC placement in the Vascular Access Unit.
Describe adverse events related to the use of taurolidine lock solutions.
Time frame: Eight and thirty days after PICC placement in the Vascular Access Unit.
Describe the difficulties encountered by healthcare professionals when using taurolidine lock solutions.
Time frame: Eight and thirty days after PICC placement in the Vascular Access Unit.
Describe the information sources used by healthcare professionals regarding taurolidine lock solutions.
Time frame: Eight and thirty days after PICC placement in the Vascular Access Unit.
Characterize the use of device vigilance in the event of adverse events related to taurolidine lock solutions.
Time frame: Eight and thirty days after PICC placement in the Vascular Access Unit.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Dec 2025.
- Individual participant dataSharing planned: No
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
An observational study of Taurolidine Lock Solution, run by University Hospital, Grenoble.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 2 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Cordélia SALOMEZ-IHL, pharmacist (+ 33 (0)4 76 76 85 27, cihl@chu-grenoble.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To characterize, through an assessment of current practices, the administration of taurolidine lock solutions as prescribed for patients who have undergone PICC implantation in the Vascular Access Unit as part of parenteral nutrition therapy. (time frame: Eight and thirty days after PICC placement in the Vascular Access Unit). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Dec 2025.